Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds

Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds
Women with newly diagnosed breast cancer who carry a mutation in their BRCA genes may continue to receive the standard pre-surgery chemotherapy regimen used for other breast cancer patients, according to findings from a Phase 2 trial. That trial, called INFORM, found that platinum chemotherapy was no more effective than current approaches in treating women with early-stage breast cancer carrying BRCA mutations. The findings of the study, “TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial),” were published in the Journal of Clinical Oncology. Platinum-based chemotherapy is known to have promising activity in BRCA-mutated breast cancers. The INFORM trial (NCT01670500) investigated whether the platinum chemotherapy agent cisplatin was better than standard chemo in women with early-stage breast cancer carrying BRCA mutations. The results showed that platinum chemo was no more effective than current approaches using doxorubicin and cyclophosphamide. "Previous studies reported that the platinum-based therapy cisplatin was effective in BRCA carriers with breast cancer," Nadine Tung, MD, lead investigator in the trial, said in a press release. "Those findings left clinicians uncertain whether to use cisplatin — an unconventional drug for treating early stage breast cancer — or whether to use the same chemotherapy regimen used for other women with breast cancer." "Prior to INFORM, no randomized prospective data existed comparing platinum to standard chemotherapy in this population of patients. Our study found that platinum-based therapy was actually no more effective than the standard first-line treatment," said Tung, director of
Subscribe or to access all post and page content.